Association of <scp>CNR1</scp> gene and cannabinoid 1 receptor protein in the human brain

Pak, Kyoungjune; Kantonen, Tatu; Pekkarinen, Laura; Nuutila, Pirjo; Nummenmaa, Lauri

doi:10.1002/jnr.25149

Cited by 4 publications

(3 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is associated with a variety of brain functions, including memory, mood, and motor control. The cannabinoid receptor type 1 (CB1) is encoded by CNR1 and is primarily involved in brain function . CNR1 is expressed in the central and peripheral nervous systems.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Transcriptome Study of rd1Mouse Brain and Association with Parkinson’s Disease

Zhou,

Yang,

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Degeneration of the retina is intrinsically associated with the pathogenesis and progression of neurodegenerative diseases. However, the cellular and molecular mechanisms underlying the association between neurodegeneration and retinal degeneration are still under exploration due to the complexity of the connectivity network of the nervous system. In this study, RNA-seq data from the brains of model retinitis pigmentosa (RP) mice and previously studied Parkinson's disease (PD) mice were analyzed to explore the commonalities between retinal degenerative and neurodegenerative diseases. Differentially expressed genes in RP were compared with neurodegenerative disease-related genes and intersecting genes were identified, including Cnr1 and Septin14. These genes were verified by quantitative realtime reverse transcription PCR and Western blotting experiments. The key proteins CNR1 and SEPTIN14 were found to be potential cotherapeutic targets for retinal degeneration and neurodegenerative disease. In conclusion, understanding the commonalities between retinal degenerative diseases and neurodegenerative processes in the brain will not only facilitate the interpretation of the underlying pathomechanisms but also contribute to early diagnosis and the development of new therapeutic strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The cannabinoid receptor type 1 (CB1) is encoded by CNR1 and is primarily involved in brain function. 36 CNR1 is expressed in the central and peripheral nervous systems. CB1 acts as an inhibitor of excitatory and inhibitory neurotransmitters.…”

Section: Resultsmentioning

confidence: 99%

Transcriptome Study of rd1Mouse Brain and Association with Parkinson’s Disease

Zhou,

Yang,

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…The latter occurred via increased gut bacterial diversity, decreased expression of pro-inflammatory genes, and increased production of anti-inflammatory regulatory micro-RNA in the gastrointestinal tract [20,[26][27][28]. THC and CBD exert their anti-inflammatory properties largely through the activation of receptors of the endocannabinoid system, particularly the cannabinoid receptor type 1 (CB1R) and 2 (CB2R), which are mainly expressed, although at different levels, in the brain and the central nervous system (CNS) [29,30], the gastrointestinal tract [25,31,32] and on immune cells [33]. By alleviating gut epithelial damage and systemic inflammation, cannabinoid treatment could have the potential to reduce systemic inflammation in PWH [34,35].…”

Section: Introductionmentioning

confidence: 99%

Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial

Bouassa

Comeau

Alexandrova

et al. 2023

Cells

View full text Add to dashboard Cite

Chronic HIV infection is characterized by persistent inflammation despite antiretroviral therapy (ART). Cannabinoids may help reduce systemic inflammation in people with HIV (PWH). To assess the effects of oral cannabinoids during HIV, ten PWH on ART were randomized (n = 5/group) to increasing doses of oral Δ9-tetrahydrocannabinol (THC): cannabidiol (CBD) combination (2.5:2.5–15:15 mg/day) capsules or CBD-only (200–800 mg/day) capsules for 12 weeks. Blood specimens were collected prospectively 7–21 days prior to treatment initiation and at weeks 0 to 14. Plasma cytokine levels were determined via Luminex and ELISA. Immune cell subsets were characterized by flow cytometry. HIV DNA/RNA were measured in circulating CD4 T-cells and sperm by ultra-sensitive qPCR. Results from both arms were combined for statistical analysis. Plasma levels of IFN-γ, IL-1β, sTNFRII, and REG-3α were significantly reduced at the end of treatment (p ˂ 0.05). A significant decrease in frequencies of PD1+ memory CD4 T-cells, CD73+ regulatory CD4 T-cells, and M-DC8+ intermediate monocytes was also observed (p ˂ 0.05), along with a transient decrease in CD28–CD57+ senescent CD4 and CD8 T-cells. Ki-67+ CD4 T-cells, CCR2+ non-classical monocytes, and myeloid dendritic cells increased over time (p ˂ 0.05). There were no significant changes in other inflammatory markers or HIV DNA/RNA levels. These findings can guide future large clinical trials investigating cannabinoid anti-inflammatory properties.

show abstract